BlossomHill Therapeutics, Inc.
Research BlossomHill Therapeutics, Inc. (BLSM) on Bullrun: market cap USD 429.10M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBLSM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 429.10M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 23.76M
- Free cash flow-USD 23.23M
Valuation Snapshot
latest market cap is USD 429.10M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 60.56M | -USD 47.99M | n/a | -3.69 | USD 136.68M | USD 22.40M | -USD 131.73M |
| FY2024 | USD 0 | -USD 30.70M | -USD 31.51M | n/a | -1.47 | USD 100.15M | USD 525.00K | -USD 72.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 429.10M | n/a | n/a | n/a |
About BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BlossomHill Therapeutics, Inc.'s market cap?
BlossomHill Therapeutics, Inc.'s market capitalization is USD 429.10M.
What does BlossomHill Therapeutics, Inc. do?
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc.